BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Monti P, Campomenosi P, Ciribilli Y, Iannone R, Aprile A, Inga A, Tada M, Menichini P, Abbondandolo A, Fronza G. Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay. Oncogene. 2003;22:5252-5260. [PMID: 12917626 DOI: 10.1038/sj.onc.1206511] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Moesslacher CS, Kohlmayr JM, Stelzl U. Exploring absent protein function in yeast: assaying post translational modification and human genetic variation. Microb Cell 2021;8:164-83. [PMID: 34395585 DOI: 10.15698/mic2021.08.756] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Voropaeva EN, Orlov YL, Pospelova TI, Gurageva AA, Voevoda MI, Maksimov VN, Seregina OB, Churkina MI. The rs78378222 prevalence and the copy loss of the protective allele A in the tumor tissue of diffuse large B-cell lymphoma. PeerJ 2020;8:e10335. [PMID: 33240649 DOI: 10.7717/peerj.10335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lopes EA, Gomes S, Saraiva L, Santos MM. Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment. CMC 2020;26:7323-36. [DOI: 10.2174/0929867325666181116124308] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
4 Voropaeva EN, Pospelova TI, Voevoda MI, Maksimov VN, Orlov YL, Seregina OB. Clinical aspects of TP53 gene inactivation in diffuse large B-cell lymphoma. BMC Med Genomics 2019;12:35. [PMID: 30871527 DOI: 10.1186/s12920-019-0484-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
5 Gomes S, Raimundo L, Soares J, Loureiro JB, Leão M, Ramos H, Monteiro MN, Lemos A, Moreira J, Pinto M, Chlapek P, Veselska R, Sousa E, Saraiva L. New inhibitor of the TAp73 interaction with MDM2 and mutant p53 with promising antitumor activity against neuroblastoma. Cancer Lett 2019;446:90-102. [PMID: 30664963 DOI: 10.1016/j.canlet.2019.01.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
6 Billant O, Léon A, Le Guellec S, Friocourt G, Blondel M, Voisset C. The dominant-negative interplay between p53, p63 and p73: A family affair. Oncotarget 2016;7:69549-64. [PMID: 27589690 DOI: 10.18632/oncotarget.11774] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
7 Billant O, Blondel M, Voisset C. p53, p63 and p73 in the wonderland of S. cerevisiae. Oncotarget 2017;8:57855-69. [PMID: 28915717 DOI: 10.18632/oncotarget.18506] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
8 Voropaeva EN, Pospelova TI, Voevoda MI, Maksimov VN. Frequency, spectrum, and functional significance of TP53 mutations in patients with diffuse large B-cell lymphoma. Mol Biol 2017;51:53-60. [DOI: 10.1134/s0026893316060224] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Sharma V, Monti P, Fronza G, Inga A. Human transcription factors in yeast: the fruitful examples of P53 and NF-кB. FEMS Yeast Res 2016;16:fow083. [PMID: 27683095 DOI: 10.1093/femsyr/fow083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhang Y, Coillie SV, Fang JY, Xu J. Gain of function of mutant p53: R282W on the peak? Oncogenesis 2016;5:e196. [PMID: 26878390 DOI: 10.1038/oncsis.2016.8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
11 Gomes S, Leão M, Raimundo L, Ramos H, Soares J, Saraiva L. p53 family interactions and yeast: together in anticancer therapy. Drug Discov Today 2016;21:616-24. [PMID: 26891980 DOI: 10.1016/j.drudis.2016.02.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
12 Lih CJ, Sims DJ, Harrington RD, Polley EC, Zhao Y, Mehaffey MG, Forbes TD, Das B, Walsh WD, Datta V, Harper KN, Bouk CH, Rubinstein LV, Simon RM, Conley BA, Chen AP, Kummar S, Doroshow JH, Williams PM. Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial. J Mol Diagn 2016;18:51-67. [PMID: 26602013 DOI: 10.1016/j.jmoldx.2015.07.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
13 Lee JG, Ahn JH, Jin Kim T, Ho Lee J, Choi JH. Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin β4 and Akt signals. Sci Rep 2015;5:12642. [PMID: 26223322 DOI: 10.1038/srep12642] [Cited by in Crossref: 29] [Cited by in F6Publishing: 39] [Article Influence: 4.1] [Reference Citation Analysis]
14 Brachova P, Mueting SR, Carlson MJ, Goodheart MJ, Button AM, Mott SL, Dai D, Thiel KW, Devor EJ, Leslie KK. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. Int J Oncol 2015;46:607-18. [PMID: 25385265 DOI: 10.3892/ijo.2014.2747] [Cited by in Crossref: 39] [Cited by in F6Publishing: 50] [Article Influence: 4.9] [Reference Citation Analysis]
15 Nobusawa A, Sano T, Yokoo S, Oyama T. Ameloblastic carcinoma developing in preexisting ameloblastoma with a mutation of the p53 gene: a case report. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology 2014;118:e146-50. [DOI: 10.1016/j.oooo.2014.03.021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
16 Bisio A, Ciribilli Y, Fronza G, Inga A, Monti P. TP53 Mutants in the Tower of Babel of Cancer Progression. Human Mutation 2014;35:689-701. [DOI: 10.1002/humu.22514] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
17 Ciribilli Y, Monti P, Bisio A, Nguyen HT, Ethayathulla AS, Ramos A, Foggetti G, Menichini P, Menendez D, Resnick MA, Viadiu H, Fronza G, Inga A. Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code. Nucleic Acids Res 2013;41:8637-53. [PMID: 23892287 DOI: 10.1093/nar/gkt657] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
18 Xie TX, Zhou G, Zhao M, Sano D, Jasser SA, Brennan RG, Myers JN. Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells. Laryngoscope 2013;123:1416-23. [PMID: 23625637 DOI: 10.1002/lary.23846] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
19 Benson NC, Daggett V. A comparison of multiscale methods for the analysis of molecular dynamics simulations. J Phys Chem B 2012;116:8722-31. [PMID: 22494262 DOI: 10.1021/jp302103t] [Cited by in Crossref: 33] [Cited by in F6Publishing: 47] [Article Influence: 3.3] [Reference Citation Analysis]
20 Ethayathulla AS, Tse PW, Monti P, Nguyen S, Inga A, Fronza G, Viadiu H. Structure of p73 DNA-binding domain tetramer modulates p73 transactivation. Proc Natl Acad Sci U S A 2012;109:6066-71. [PMID: 22474346 DOI: 10.1073/pnas.1115463109] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
21 Herrmann LJ, Heinze B, Fassnacht M, Willenberg HS, Quinkler M, Reisch N, Zink M, Allolio B, Hahner S. TP53 germline mutations in adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab 2012;97:E476-85. [PMID: 22170717 DOI: 10.1210/jc.2011-1982] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 6.5] [Reference Citation Analysis]
22 Ginsburg OM, Akbari MR, Aziz Z, Young R, Lynch H, Ghadirian P, Robidoux A, Londono J, Vasquez G, Gomes M, Costa MM, Dimitrakakis C, Gutierrez G, Pilarski R, Royer R, Narod SA. The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30. Familial Cancer 2009;8:563-7. [DOI: 10.1007/s10689-009-9287-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
23 Monti P, Ciribilli Y, Jordan J, Menichini P, Umbach DM, Resnick MA, Luzzatto L, Inga A, Fronza G. Transcriptional functionality of germ line p53 mutants influences cancer phenotype. Clin Cancer Res 2007;13:3789-95. [PMID: 17606709 DOI: 10.1158/1078-0432.CCR-06-2545] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
24 Magrini R, Russo D, Fronza G, Inga A, Menichini P. The kinetics of p53-binding and histone acetylation at target promoters do not strictly correlate with gene expression after UV damage. J Cell Biochem 2007;100:1276-87. [PMID: 17063487 DOI: 10.1002/jcb.21122] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
25 Kudawara I, Matsumine A, Ohzono K. Analysis of germline and tumor mutations of p53 gene in familial occurrence of soft tissue sarcomas. J Surg Oncol 2007;95:347-50. [PMID: 17192950 DOI: 10.1002/jso.20720] [Reference Citation Analysis]
26 Pérez LO, Abba MC, Dulout FN, Golijow CD. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006; 12(9): 1426-1429 [PMID: 16552814 DOI: 10.3748/wjg.v12.i9.1426] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
27 Smardová J, Smarda J, Koptíková J. Functional analysis of p53 tumor suppressor in yeast. Differentiation 2005;73:261-77. [PMID: 16138827 DOI: 10.1111/j.1432-0436.2005.00028.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
28 Mager WH, Winderickx J. Yeast as a model for medical and medicinal research. Trends Pharmacol Sci 2005;26:265-73. [PMID: 15860374 DOI: 10.1016/j.tips.2005.03.004] [Cited by in Crossref: 140] [Cited by in F6Publishing: 125] [Article Influence: 8.2] [Reference Citation Analysis]
29 Zhu ZZ, Cong WM, Liu SF, Dong H, Zhu GS, Wu MC. Homozygosity for Pro of p53 Arg72Pro as a potential risk factor for hepatocellular carcinoma in Chinese population. World J Gastroenterol 2005; 11(2): 289-292 [PMID: 15633234 DOI: 10.3748/wjg.v11.i2.289] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 30] [Article Influence: 1.7] [Reference Citation Analysis]
30 Gasco M, Crook T. p53 family members and chemoresistance in cancer: what we know and what we need to know. Drug Resistance Updates 2003;6:323-8. [DOI: 10.1016/j.drup.2003.11.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]